๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Treatment of hypercholesterolemia by precipitation of lipoproteins with dextran sulfate

โœ Scribed by Dr. G. Delbert Antwiler; Peter C. Dau; Donn D. Lobdcll


Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
472 KB
Volume
4
Category
Article
ISSN
0733-2459

No coin nor oath required. For personal study only.

โœฆ Synopsis


An on-line continuous system for the selective precipitation of low-density lipoproteins (LDL) and very lowdensity lipoproteins (VLDL) has been devised and tested. This system conserves high-density lipoproteins (HDL) and other plasma macromolecules. LDL and VLDL are precipitated from plasma using 10-35 mg/dl dextran sulfate (M, 5,000) in the presence of 55 mM calcium with a reduced concentration of monovalent cations. The plasma is obtained by membrane filtration of whole blood using the COBE Centrye TPE System (Cobe Laboratories Inc, Lakewood, Co.). The precipitated LDL plus VLDL is removed by filtration, and the electrolytes are restored by dialysis. The plasma minus LDL plus VLDL is then returned to the patient.

Four patients with heterozygous familial hypercholesterolemia (type 11) were treated 70 times. The mean pretreatment serum cholesterol was 383 mg/dl. The mean reductions in plasma components were: LDL plus VLDL 63%; HDL 27%; fibrinogen 19%; albumin 15%; IgG 20%; IgA 19%; IgM 25%; C3 30%: and C4 27%. The cholesterol returned to near normal values in approximately 2 weeks after each treatment.

Four normal volunteers were each treated one time. These individuals had a mean pretreatment serum cholesterol of 201 mgldl. The mean reduction in plasma components were: LDL plus VLDL 70%; HDL 27%; fibrinogen 24%; albumin 14%; IgG 18%; IgA 17%; IgM 20%: C3 27%; C4 22%; C3 proactivator 12%; alpha,antitrypsin 17 %; ceruloplasma 17 %; transferin 18%; alpha2-macroglobulin 17 %; and orosomucoid 13 %.

It is our conclusion that dextran sulfate precipitation is an effective on-line means of selectively removing LDL plus VLDL from plasma while conserving HDL and other plasma macromolecules. The capacity of the system is limited only to the size of the filter (currently estimated at over 30 gm of cholesterol). The reduction of LDL plus VLDL is limited only by the quantity of plasma processed while the reduction in the other plasma components is virtually independent of plasma volume processed.


๐Ÿ“œ SIMILAR VOLUMES


Reduction of low-density lipoproteins wi
โœ G. Delbert Antwiler; Peter C. Dau; Donn D. Lobdell ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 822 KB

A novel on-line system for the selective precipitation of low-density lipoprotein (LDL) using dextran sulfate has been devised and tested in four patients with heterozygous familial hypercholesterolemia (type 11). The mean pretreatment serum cholesterol was 410 mg/dl. Plasma was generated by membran

Treatment of hypercholesterolemia with h
โœ Robert S. Lees; Norma N. Holmes; Robert W. Stadler; Sherrif F. Ibrahim; Ann M. L ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 576 KB

Familial hypercholesterolemia (FH) can cause early disability and death from premature atherosclerotic cardiovascular disease. Patients homozygous for the disease have very high plasma cholesterol, extensive xanthomatosis, and die from atherosclerosis in childhood or early adulthood. Past attempts t

Treatment of hypercholesterolemia by che
โœ Shinji Yokoyama ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 555 KB

Dextran sulfate (Mr 5,000) was covalently linked to porous cellulose beads, and the dissociation constant (Kd) and the maximum binding level (S) of the beads were calculated for the human plasma lipoproteins VLDL, LDL, and HDL. The S values for VLDL and LDL were 2 and 7 g cholesterol/liter of the we

Decrease of thyroid hormones in patients
โœ S. Pintus; Dr. P. Pintus; C. Piras; A. Loviselli; S. Muntoni ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 187 KB

Removal of low-density lipoproteins from plasma by dextran sulfate adsorption (DSA) in FH patients entails a decrease in plasma levels of thyroid hormones (-28.5% and -18.78, respectively, for T3 and T4). This suggests that FH patients have a greater than normal fraction of thyroid hormones bound to